Figure 1.
Cell viability (%) after 48 hours across three AML cell lines, KG-1A (A), U-937 (B), and K-562 (C). Wild-type (W-T) and Doxorubicin-Resistant (D-R) clones were treated with either control diluent, Doxorubicin, MIA-602, or a combination of Doxorubicin and MIA-602. Treatment with MIA-602 was effective in reducing cell viability across all cancer cell lines.
